But I am now in biochemical recurrence stage of prostate cancer status post prostatectomy. What is my prognosis if...

I understand your concern about biochemical recurrence after prostatectomy. Let me provide some evidence-based information about prognosis related to PSA doubling time (PSADT).

According to the NCCN Guidelines for Prostate Cancer (2023), PSA doubling time is one of the most important predictive factors for outcomes in biochemical recurrence. Your PSADT of >15 months is actually a favorable prognostic factor:

1. According to ASCO Guidelines, patients with a PSA doubling time >15 months generally have a better prognosis compared to those with shorter doubling times. Specifically, longer PSADT (>15 months) is associated with:

• Lower risk of developing metastatic disease
• Better overall survival rates
• More time before requiring additional treatments

The American Urological Association (AUA) guidelines indicate that patients with:

• PSADT >15 months have approximately 80-85% chance of being metastasis-free at 5 years
• This longer doubling time suggests a less aggressive disease pattern

However, it's important to note that prognosis depends on multiple factors, including:

• Initial PSA level
• Gleason score
• Surgical margins status
• Time since surgery
• Other health conditions

I strongly recommend discussing your specific situation with your healthcare team, as they can provide personalized prognostic information based on all your individual factors. They can also help determine the most appropriate monitoring or treatment strategy for your case.

Would you like me to provide more information about recommended monitoring strategies for biochemical recurrence with your PSADT profile?